Overview

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.

Phase:

Phase 2

Details

Lead Sponsor:

Mirati Therapeutics Inc.

Treatments:

Antibodies, Monoclonal
Mocetinostat
Nivolumab